Compare Mizuho Financial Group Inc. Sponosred ADR (Japan) (MFG) vs Maravai LifeSciences Holdings Inc. Class A Common Stock (MRVI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Mizuho Financial Group Inc. Sponosred ADR (Japan) vs Maravai LifeSciences Holdings Inc. Class A Common Stock — how do they compare? Mizuho Financial Group Inc. Sponosred ADR (Japan) trades at $9.99 (market cap $127.56B), while Maravai LifeSciences Holdings Inc. Class A Common Stock trades at $6.56 (market cap $972.90M). The key difference: Mizuho Financial Group Inc. Sponosred ADR (Japan) is far larger — about 131.1× Maravai LifeSciences Holdings Inc. Class A Common Stock's market cap, and Mizuho Financial Group Inc. Sponosred ADR (Japan) pays a 1.73% dividend while Maravai LifeSciences Holdings Inc. Class A Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold Mizuho Financial Group Inc. Sponosred ADR (Japan) for 6 Days and Maravai LifeSciences Holdings Inc. Class A Common Stock for 0 Days on average.
| MFG | MRVI | |
|---|---|---|
Market Cap | $127.56B | $972.90M |
Volume | 2,374,252 | 4,325,710 |
Sector | Financials | Health |
52-Week High | $11.45 | $9.00 |
52-Week Low | $6.23 | $2.83 |
Typical Hold Time | 6 Days | 0 Days |
Enterprise Value | $34.95T | $1.08B |
Dividend Yield | 1.73% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Mizuho Financial Group (MFG) trades at $10.60, up slightly by 0.09% on the day, with a bearish technical signal from moving averages but neutral oscillators. The company reported strong earnings beats in recent quarters, with Q2 2026 EPS of $0.22 exceeding the $0.17 estimate. Revenue grew to $3.65T in 2025, with a net income margin of 30.42% and a P/E ratio of 14.96, indicating reasonable valuation. Recent news highlights institutional stake adjustments and positive CRA ratings.
MFG presents a mixed outlook; earnings momentum and solid profitability support upside, but bearish technicals and analyst caution (60% hold rating) suggest near-term pressure. Key risks include declining cash flow trends and rising debt-to-asset ratio, while institutional interest and dividend growth potential offer opportunities for long-term investors.
Maravai LifeSciences (MRVI) trades at $6.53, down 7.51% in the last session amid mixed signals. The stock shows improving fundamentals with Q2 2026 revenue growth of 9% and three consecutive earnings beats, though it remains unprofitable with a -37.07% net margin. Technical analysis indicates neutral positioning with key support at $6 and resistance at $7. Recent news highlights patent expansions in China and institutional accumulation.
The outlook remains cautiously optimistic with analyst consensus pointing to 7% upside potential to the $7.00 price target. Key opportunities include margin expansion and RNA technology leadership, while risks center on persistent cash burn and competitive pressures in life sciences. The stock offers speculative growth potential for risk-tolerant investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Mizuho Financial Group Inc. Sponosred ADR (Japan)
Mizuho Financial Group is a Japanese financial services company offering banking, trust, securities, and asset management services. It serves retail, corporate, and institutional clients globally.
Read more on MFG →About Maravai LifeSciences Holdings Inc. Class A Common Stock
Maravai LifeSciences Holdings Inc. is a life sciences company supporting drug therapy, diagnostic, and vaccine development through four operating brands: TriLink BioTechnologies (nucleic acid and mRNA synthesis), Cygnus Technologies (biologics safety testing), Glen Research (oligonucleotide synthesis materials), and Alphazyme (enzyme manufacturing). It serves biotech and biopharma customers from discovery through commercial manufacturing.
Read more on MRVI →
